Wright Bonilla Quoted on DOJ Brief

05 November 2010 BNA’s Patent, Trademark & Copyright Journal News

Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BNA’s Patent, Trademark & Copyright Journal on November 5, 2010 titled "DOJ's ‘Questionable Reinterpretation' of DNA Patentability Disappoints Patent Community." Wright Bonilla discusses the patent community’s backlash against a brief filed by the U.S. Department of Justice as a friend of the court in the Myriad case on the patentability of genetic materials. She cautions against an overreaction to the DOJ's brief, stating that Myriad’s composition claims directed to cDNA are patent eligible. She adds that the DOJ brief asserts this patent eligibility and meets the threshold of Section 101 of the Patent Act.

Insights

The DOL Tries to Say Goodbye—And Seriously, We Mean It—to the 80/20 Rule for Tipped Employees
21 October 2019
Labor & Employment Law Perspectives
To Stalk or Not to Stalk . . . That Is the Question – Using Social Media for Applicant Review
21 October 2019
Labor & Employment Law Perspectives
New Patent Subject Matter Eligibility Updates Seeks Examination Predictability
21 October 2019
Legal News: Intellectual Property
Cryptocurrency in China is like BIG BROTHER in 1984!
20 October 2019
Internet, IT & e-Discovery Blog
PATH Summit 2019
18-20 December 2019
Arlington, VA
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.